Iradimed Valuation
| IRMD Stock | USD 99.84 3.24 3.14% |
At this time, the firm appears to be undervalued. Iradimed retains a regular Real Value of $112.24 per share. The prevalent price of the firm is $99.84. Our model calculates the value of Iradimed from evaluating the firm fundamentals such as Return On Asset of 0.16, current valuation of 1.26 B, and Return On Equity of 0.25 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Iradimed's valuation include:
Price Book 13.8602 | Enterprise Value | Enterprise Value Ebitda 48.1992 | Price Sales 15.6453 | Forward PE 48.5437 |
Undervalued
Today
Please note that Iradimed's price fluctuation is very steady at this time. Calculation of the real value of Iradimed is based on 3 months time horizon. Increasing Iradimed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iradimed stock is determined by what a typical buyer is willing to pay for full or partial control of Iradimed Co. Since Iradimed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iradimed Stock. However, Iradimed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 99.84 | Real 112.24 | Target 120.0 | Hype 99.36 |
The real value of Iradimed Stock, also known as its intrinsic value, is the underlying worth of Iradimed Company, which is reflected in its stock price. It is based on Iradimed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Iradimed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Iradimed Co helps investors to forecast how Iradimed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iradimed more accurately as focusing exclusively on Iradimed's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Iradimed's intrinsic value based on its ongoing forecasts of Iradimed's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Iradimed's closest peers. If more than one evaluation category is relevant for Iradimed we suggest using both methods to arrive at a better estimate.
Iradimed Cash |
|
Iradimed Total Value Analysis
Iradimed Co is currently expected to have valuation of 1.26 B with market capitalization of 1.31 B, debt of 154.69 K, and cash on hands of 55.59 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Iradimed fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.26 B | 1.31 B | 154.69 K | 55.59 M |
Iradimed Investor Information
About 37.0% of the company shares are held by company insiders. The company last dividend was issued on the 23rd of February 2026. Based on the measurements of operating efficiency obtained from Iradimed's historical financial statements, Iradimed Co may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 30.9 M | 29.5 M |
|
|
Iradimed Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Iradimed has an asset utilization ratio of 85.24 percent. This indicates that the Company is making $0.85 for each dollar of assets. An increasing asset utilization means that Iradimed Co is more efficient with each dollar of assets it utilizes for everyday operations.Iradimed Profitability Analysis
Based on the measurements of profitability obtained from Iradimed's financial statements, Iradimed Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Iradimed's ability to earn profits and add value for shareholders.Net Income | First Reported 2012-12-31 | Previous Quarter 5.6 M | Current Value 6.4 M | Quarterly Volatility 1.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.7675 |
|
| |||||
| Net Profit Margin | 0.15 | 0.2682 |
|
| |||||
| Return On Assets | 0.17 | 0.22 |
|
| |||||
| Return On Equity | 0.2 | 0.25 |
|
|
For Iradimed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Iradimed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Iradimed utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Iradimed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Iradimed over time as well as its relative position and ranking within its peers.
Iradimed Earnings per Share Projection vs Actual
The next projected EPS of Iradimed is estimated to be 0.45 with future projections ranging from a low of 0.44 to a high of 0.45. Iradimed's most recent 12-month trailing earnings per share (EPS TTM) is at 1.75. Please be aware that the consensus of earnings estimates for Iradimed Co is based on EPS before non-recurring items and includes expenses related to employee stock options.Iradimed Earnings Estimation Breakdown
The calculation of Iradimed's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Iradimed is estimated to be 0.45 with the future projection ranging from a low of 0.44 to a high of 0.45. Please be aware that this consensus of annual earnings estimates for Iradimed Co is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.44 Lowest | Expected EPS | 0.45 Highest |
Iradimed Earnings Projection Consensus
Suppose the current estimates of Iradimed's value are higher than the current market price of the Iradimed stock. In this case, investors may conclude that Iradimed is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Iradimed's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 2 | 92.01% | 0.54 | 0.45 | 1.75 |
Iradimed Ownership Allocation
The market capitalization of Iradimed is $1.31 Billion. Over half of Iradimed's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.Iradimed Profitability Analysis
The company reported the previous year's revenue of 83.81 M. Net Income was 19.23 M with profit before overhead, payroll, taxes, and interest of 64.32 M.Iradimed Past Distributions to stockholders
| 30th of December 2025 | ||
| 25th of November 2025 | ||
| 28th of August 2025 | ||
| 30th of May 2025 | ||
| 5th of March 2025 | ||
| 25th of November 2024 | ||
| 30th of August 2024 | ||
| 30th of May 2024 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Iradimed's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Iradimed and how it compares across the competition.
About Iradimed Valuation
The stock valuation mechanism determines Iradimed's current worth on a weekly basis. Our valuation model uses a comparative analysis of Iradimed. We calculate exposure to Iradimed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iradimed's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 64.3 M | 32.7 M | |
| Pretax Profit Margin | 0.34 | 0.19 | |
| Operating Profit Margin | 0.31 | 0.18 | |
| Net Profit Margin | 0.27 | 0.15 | |
| Gross Profit Margin | 0.77 | 0.62 |
Iradimed Quarterly Retained Earnings |
|
A single share of Iradimed represents a small ownership stake in the entity. As a stockholder of Iradimed, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Iradimed Dividends Analysis For Valuation
The current year's Dividend Payout Ratio is expected to grow to 0.86, whereas Dividends Paid is forecasted to decline to about 8.5 M. . At present, Iradimed's Earnings Yield is projected to increase slightly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 85.36, whereas Retained Earnings Total Equity is forecasted to decline to about 30.9 M.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 15.7 M | 8.5 M | |
| Dividend Yield | 0.01 | 0.01 | |
| Dividend Payout Ratio | 0.67 | 0.86 | |
| Dividend Paid And Capex Coverage Ratio | 1.36 | 1.29 |
There are various types of dividends Iradimed can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Iradimed shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Iradimed Co directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Iradimed pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Iradimed by the value of the dividends paid out.
Iradimed Growth Indicators
Investing in growth stocks can be very risky. If the company such as Iradimed does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.9 M | |
| Quarterly Earnings Growth Y O Y | 0.247 | |
| Forward Price Earnings | 48.5437 |
Iradimed Current Valuation Indicators
Valuation refers to the process of determining the present value of Iradimed Co and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Iradimed we look at many different elements of the entity such as Iradimed's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Iradimed, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Iradimed's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Iradimed's worth.Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |